Skip to main content

Table 2 Atrial fibrillation clinical management according to patient clusters

From: Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

  Cluster 1 Cluster 2 Cluster 3 P
Antithrombotic treatment
Any antiplatelet, n (%) 9356 708 (19.5) 304 (11.0) 812 (27.5) < .001
Any OAC, n (%) 9359 3143 (86.5) 2306 (83.2) 2563 (86.7) < .001
Any VKA, n (%) 9358 1833 (50.5) 1163 (42.0) 1639 (55.5) < .001
Any NOAC, n (%) 9354 1314 (36.2) 1145 (41.3) 925 (31.3) < .001
Antithrombotic pattern, n (%)     < .001
  No antithrombotic 217 (6.0) 318 (11.5) 142 (4.8)  
  Only antiplatelet 273 (7.5) 147 (5.3) 250 (8.5)  
  Only VKA 1524 (42.0) 1059 (38.2) 1228 (41.6)  
  Only NOAC 1182 (32.6) 1089 (39.3) 773 (26.2)  
  Antiplatelet + OAC 435 (12.0) 157 (5.7) 562 (19.0)  
Primary management (before admission)     < .001
Primary management strategy, n (%) 7753     < .001
  Rate control 1371 (45.3) 802 (36.5) 1317 (52.0)  
  Rhythm control 1203 (39.8) 1083 (49.3) 852 (33.7)  
  Observation 452 (14.9) 311 (14.2) 362 (14.3)  
Primary ECV, n (%) 7350 693 (24.1) 604 (28.5) 476 (20.2) < .001
Primary PCV, n (%) 7281 730 (25.6) 629 (29.9) 621 (26.6) .003
Primary catheter ablation, n (%) 7531 171 (5.8) 181 (8.4) 108 (4.4) < .001
Management during admission/consultation     <.001
Intervention planned/performed, n (%) 9363 1285 (34.6) 1150 (41.5) 984 (33.3) <.001
ECV, n (%) 3392 566 (45.0) 628 (54.6) 379 (38.5) < .001
PCV, n (%) 3392 304 (24.2) 204 (17.7) 245 (24.9) < .001
Catheter ablation, n (%) 3392 176 (14.0) 261 (22.7) 100 (10.2) < .001
Management strategy at discharge, n (%)     < .001
  Rate control 1724 (47.5) 984 (35.5) 1522 (51.7)  
  Rhythm control 1365 (37.6) 1333 (48.1) 981 (33.3)  
  Observation 537 (14.8) 452 (16.3) 442 (15.0)  
ABC pathway adherence, n (%) 666 (30.8) 655 (34.5) 431 (26.2) < .001
  1. Legend: ECV electrical cardioversion, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anticoagulant, PCV pharmacological cardioversion, VKA vitamin K antagonist